News

NORTH BRUNSWICK, N.J., June 29, 2021 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases based on a portfolio built around gelsolin technology, announced that it was awarded a contract from Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant …

June 2021: BioAegis Awarded BARDA Contract to Advance Development of Gelsolin, a Novel Host-Directed Human Protein, for Patients with Sepsis and Severe Infection Read More »

This distinguished awards program celebrates the unstoppable entrepreneurs whose unbounded ambitions deliver innovation, growth and prosperity that transform our world.   NORTH BRUNSWICK, N.J., June 4, 2021 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases based on a portfolio built around gelsolin technology, announces …

June 2021: EY Announces Dr. Susan L. Levinson of BioAegis Therapeutics Inc. as an Entrepreneur Of The Year 2021 New Jersey Award Finalist Read More »

Gelsolin mitigates vascular damage by preventing release of IL-1β microparticles after trauma of high pressure and decompression. Gelsolin is non-immunosuppressive unlike current treatments to quell inflammatory cytokines. MORRISTOWN, N.J., April 8, 2021 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases based on a portfolio …

April 2021: Study Identifies New Role of BioAegis’ ‘Inflammation Regulator’ Gelsolin Relevant for a Range of Inflammatory Diseases Read More »

MORRISTOWN, N.J., March 15, 2021 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases based on a portfolio built around gelsolin technology, announced today that it has completed enrollment for its Phase 2 study of hospitalized patients with severe COVID-19 pneumonia. This study assesses BioAegis’ …

March 2021: BioAegis Therapeutics Completes Recruitment for Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment Read More »

Most of the attention right now is on vaccines, but vaccines are only part of the battle against COVID-19. Dr. Mark DiNubile, Chief Medical Officer at BioAegis, joins KYW Newsradio In Depth to talk about what’s out there right now, the science behind COVID-19 treatments, and why he believes so strongly that gelsolin therapy can …

March 2021: KYW InDepth Podcast – Vaccines are just part of the battle. Good therapeutics are needed to fight COVID-19 as well. Read More »

MORRISTOWN, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around gelsolin technology, announced today that studies from three independent groups of investigators, including the NIH, have reported that low levels of gelsolin are associated with severity and organ …

February 2021: NIH and Other Independent Studies Confirm Low Levels of BioAegis’ ‘Inflammation Regulator Protein,’ Gelsolin, Associated with COVID-19 Severity Read More »

No drug-related safety signals identified by the independent Data and Safety Monitoring Board. MORRISTOWN, N.J., Nov. 15, 2020 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around gelsolin technology, announced that it has expanded its clinical trial in severe COVID-19 …

November 2020: BioAegis Therapeutics Expands Phase 2 COVID-19 Treatment Clinical Trial in EU for Inflammation Regulator Read More »

MORRISTOWN, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around gelsolin technology, announces publication of “Recombinant Human Plasma Gelsolin Improves Survival and Attenuates Lung Injury in a Murine Model of Multidrug-Resistant Pseudomonas aeruginosa Pneumonia.” Recombinant human plasma gelsolin …

September 2020: BioAegis Therapeutics Announces Study Indicating Gelsolin Treatment Improves Survival and Reduces Lung Injury in Antibiotic Resistant Pneumonia Read More »

BioAegis Conducting COVID-19 Clinical Trial of Gelsolin Therapeutic Morristown, NJ, August 17, 2020 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around gelsolin technology, announced today that recent publications of independent studies have reported that low levels of gelsolin are …

August 2020: Independent Studies Confirm Low Levels of Immune System Protein, Gelsolin, Associated with COVID-19 Severity Read More »